세계의 습진 치료제 시장(2024-2028년)

The eczema therapeutics market is forecasted to grow by USD 5.81 bn during 2023-2028, accelerating at a CAGR of 10.28% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing product launches for treating eczema, and increase in demand for over-the-counter (OTC) eczema drugs among end-users.

Technavio's eczema therapeutics market is segmented as below:

By Application

• Atopic dermatitis
• Contact dermatitis
• Other indication

By Distribution Channel

• Hospital and clinics
• Online pharmacies
• Retail pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising adoption of telemedicine platforms in eczema therapeutics as one of the prime reasons driving the eczema therapeutics market growth during the next few years. Also, growing adoption of biologic therapies for eczema treatment and increasing healthcare expenditure surging demand for eczema therapeutics will lead to sizable demand in the market.

The report on the eczema therapeutics market covers the following areas:

• Eczema therapeutics market sizing
• Eczema therapeutics market forecast
• Eczema therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics market vendors that include AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global eczema therapeutics market 2018 - 2022
• 4.2 Application Segment Analysis 2018 - 2022
• 4.3 Distribution channel Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Application

• 6.1 Market segments
• 6.2 Comparison by Application
• 6.3 Atopic dermatitis - Market size and forecast 2023-2028
• 6.4 Contact dermatitis - Market size and forecast 2023-2028
• 6.5 Other indication - Market size and forecast 2023-2028
• 6.6 Market opportunity by Application

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• 7.2 Comparison by Distribution Channel
• 7.3 Hospital and clinics - Market size and forecast 2023-2028
• 7.4 Online pharmacies - Market size and forecast 2023-2028
• 7.5 Retail pharmacies - Market size and forecast 2023-2028
• 7.6 Market opportunity by Distribution Channel

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 Germany - Market size and forecast 2023-2028
• 9.9 UK - Market size and forecast 2023-2028
• 9.10 China - Market size and forecast 2023-2028
• 9.11 Canada - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 AbbVie Inc.
• 12.4 Alliance Pharma PLC
• 12.5 Amneal Pharmaceuticals Inc.
• 12.6 AstraZeneca PLC
• 12.7 Bausch Health Companies Inc.
• 12.8 Bayer AG
• 12.9 Cadila Pharmaceuticals Ltd.
• 12.10 Eli Lilly and Co.
• 12.11 LEO Pharma AS
• 12.12 Lupin Ltd.
• 12.13 Merck and Co. Inc.
• 12.14 Novartis AG
• 12.15 Pfizer Inc.
• 12.16 Sanofi SA
• 12.17 Viatris Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations